Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-01-06
2010-06-01
Weddington, Kevin (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S267000
Reexamination Certificate
active
07727994
ABSTRACT:
The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2Areceptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2Areceptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2Areceptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor. The present invention further provides methods of prolonging effective treatment of Parkinson's disease by administering an adenosine A2Areceptor antagonist singly or together with a dopamine agonist, and/or a COMT inhibitor, and/or a MAO inhibitor without prior or subsequent administration of L-DOPA, delaying or removing on-set of L-DOPA motor complication.
REFERENCES:
patent: 5484920 (1996-01-01), Suzuki et al.
patent: 5543415 (1996-08-01), Suzuki et al.
patent: 5587378 (1996-12-01), Suzuki et al.
patent: 6608085 (2003-08-01), Gillespie et al.
patent: 6787541 (2004-09-01), Gillespie et al.
patent: 1 016 407 (2000-07-01), None
patent: WO 02/055524 (2002-07-01), None
patent: WO 02/080957 (2002-10-01), None
Konda et al., “Adenosine A2a Antagonist: A Novel Antiparkisonian Agent that Does Not Provoke Dyskinesia in Parkinsonian Monkeys”, Annals of Neurology, vol. 43, No. 4, pp. 507-513 (1998).
Grondin et al., “Antiparkinsonian effect of a new selective adenosine A2a receptor antagonist in MPTP-treated monkeys”, Neurology, vol. 52, pp. 1673-1677 (1999).
Hashimoto (“Pathophysiology of Abnormal Movements in Parkinson's Disease”, Nippon Rinsho, Oct. 2000, 58(1): 1994-1999; Abstract Only).
Kanda, et al., “Combined Use of the Adenosine A2AAntagonist KW-6002 with L-DOPA or with Selective D1 or D2 . . .”,Experimental Neurology, vol. 162 (2000), pp. 321-327.
Rashad Net University, Parkinson's Disease: Update, pp. 1-14, www.rashaduniversity.com/mrashad/padiup.html (2005).
Sundstrom, et al., “Chronic neurochemical and behavioral changes in MPTP-lesioned . . .”, Brain Research, vol. 528 (1990) 181-88.
Fredriksson, et al., “Synergistic interactions between NMDA-antagonists and L-Dopa on activity in MPTP-treated mice”, J. Neural Transm, vol. 97 (1994) 197-209.
Ossowska, et al., “Blockage of the metabotropic glutamate receptor subtype 5 (mGluR5) products . . .”, Neuropharmacology, vol. 41 (2001) 413-20.
Ungerstedt, “Postsynaptic Supersensitivity after 6-Hydroxy-dopamine Induced Degeneration . . .”, Acta Physio. Scand., vol. 367 (1971) 69-93.
Spooren, et al., “Effects of the prototypical mGlu5 receptor antagonist . . .”, European Journal of Pharmacology, vol. 406 (2000) 403-10.
Cardoso, et al., “Dystonia and Dyskinesia”, Neuropsychiatry of the Basal Ganglia, vol. 20, No. 4 (1997) 821-38.
Diaz-Cabiale, et al, “Adenosine A2A agonist CGS 21680 decreases the affinity of dopamine D2 receptors for dopamine in human striatum”, Neurochemistry, vol. 12, No. 9 (2001) 1831-34.
Ferre, et al, “Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease”, Parkinsonism and Related Disorders, vol. 7 (2001) 235-41.
Webster Ross, et al., “Association of Coffee and Caffeine Intake With the Risk of Parkinson Disease”, JAMA, vol. 283, No. 20 (2000) 2674-79.
Popoli, et al., “Effects of SCH 58261, an Adenosine A2A Receptor Antagonist, on Quinpirole-Induced Turning in 6- Hydroxydopamine-Lesioned Rats: Lack of Tolerance after Chronic Caffeine Intake”, Neuropyschopharmacology, vol. 22, No. 5 (2000) 522-29.
Koga, et al., “Adenosine A2A receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats”, European Journal of Pharmacology, vol. 408 (2000) 249-55.
Shiozaki, et al, “Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP”, Psychopharmacology, vol. 147 (1999) 90-5.
Kanda, et al., “Adenosine A2A receptors modify motor function in MPTP-treated common marmosets”, Neuropharmacology, vol. 9, No. 12 (1998) 2857-60.
Ferre, et al, “Adenosine-dopamine receptor-receptor interactions as an integrative mechanisms in the basal ganglia”, TINS, vol. 20, No. 10 (1997) 482-87.
Richardson, et al, “Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease”, TiPS, vol. 18 (1997) 338-44.
Fenu, et al., “Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned”, European Journal of Pharmacology, vol. 321 (1997) 143-47.
Pinna, et al., “Blockage of A2A Adenosine Receptors Positively Modulates Turning Behaviour and c-Fos Expression Induced by D1 Agonists in Dopamine-denervated Rats”, European Journal of Neurosciences, vol. 8, No. 6 (1996) 1176-81.
Mally, et al., “Potential Role of Adenosine Antagonist Therapy in Pathological Tremor Disorders”, Pharmacol. Ther., vol. 72, No. 3 (1996) 243-50.
Pollack, et al., “Adenosine Antagonists Potentiate D2 Dopamine-Dependent Activation of Fos in the Striatopallidal Pathway”, Neurosciences, vol. 68, No. 3 (1995) 721-28.
Mally, et al., “The effect of theophylline on parkinsonian symptoms”, J. Pharm. Pharmacol., vol. 46, No. 6 (1994) 515-17.
Kanda, et al., “KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity”, European Journal of Pharmacology, vol. 256 (1994) 263-68.
Schiffmann, et al., “Adenosine A2 Receptors Regulate the Gene Expression of Striatopallidal and Striatonigral Neurons”, The Journal of Neurosciences, vol. 13, No. 3 (1993) 1080-87.
Ferre, et al., “Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes”, Proc. Natl. Acad. Sci., vol. 88 (1991) 7238-41.
Popoli, et al., “Akinesia due to catecholamine depletion in mice is prevented by caffeine. Further evidence for an involvement of adenosinergic system in the control of motility”, J. Pharm. Pharmacol., vol. 43, No. 4 (1991) 280-81.
Stromberg, et al., “Further Studies on the Behavioural and Biochemical Interaction between Caffein and L-DOPA”, Journal of Neural Transmission, vol. 34, No. 4 (1973) 241-52.
Grondin, et al., “Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys”, Neurology, vol. 52, No. 8 (1999) 1673-77.
Kanda, et al., “Adenosine A2A Antagonist: A Novel Antiparkinsonian Agent that Does Not Provoke Dyskinesia in Parkinsonian Monkeys”, Ann Neurol, vol. 43, No. 4 (1998), 507-13.
Karasawa Akira
Kase Hiroshi
Kuwana Yoshihisa
Mori Akihisa
Ohsawa Yutaka
Fitzpatrick ,Cella, Harper & Scinto
Kyowa Hakko Kirin Co., Ltd.
Weddington Kevin
LandOfFree
Methods of treating patients suffering from movement disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating patients suffering from movement disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating patients suffering from movement disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4203022